Viraj Shah
@virajshahr
Followers
44
Following
117
Media
4
Statuses
49
MBBS graduate | CardioOncology postdoc research fellow @VascBioCenter SETH GSMC alumnus #chiefskingdom
Augusta, GA
Joined August 2024
Excellent work by #teamGuha chipping away at #prostatecancer disparities. This is one look at SOCIO-Economic position which is one of the SDOH which affects these men. See detailed tweetorial below. Also read our work on rurality - https://t.co/XcKk7gmSFJ Cc: @PCFnews
New in JNCI Cancer Spectrum‼️ Socioeconomic position (SEP) meaningfully predicts cardiovascular🫀 (CV) outcomes in men with #prostate_cancer. We examined how neighborhood disadvantage shapes long-term CV and survival risks #cardiooncology #CancerResearch
https://t.co/68G6lZ6Bxk
1
6
14
New in JNCI Cancer Spectrum‼️ Socioeconomic position (SEP) meaningfully predicts cardiovascular🫀 (CV) outcomes in men with #prostate_cancer. We examined how neighborhood disadvantage shapes long-term CV and survival risks #cardiooncology #CancerResearch
https://t.co/68G6lZ6Bxk
3
3
7
Our editorial expands on the findings of the original study that sparked important discussions in our field: “Cardiovascular Surveillance in Patients Receiving Combination BRAF/MEK Inhibitor Therapy,” now published in #JACC: CardioOncology. @avirupguha @virajshahr
#cardiooncology
Excited to share our latest work, “Cardiovascular Surveillance in BRAF/MEK Inhibitor Therapy: Early Lessons,” now published in JACC: CardioOncology. Worth a quick look: a table summarizing key cardiovascular signals emerging from recent BRAF/MEKi data. Link to the full article:
1
1
3
Excited to share our latest work, “Cardiovascular Surveillance in BRAF/MEK Inhibitor Therapy: Early Lessons,” now published in JACC: CardioOncology. Worth a quick look: a table summarizing key cardiovascular signals emerging from recent BRAF/MEKi data. Link to the full article:
0
1
15
Final (#6) presentation of #AHA25 by @MCG_AUG student @sathvika_n focused on disparities in clinical trials - take home - Among 284 Southern U.S. cities, only 26% contained a Phase III lipid-lowering trial site, with a median drive time of 36 minutes to the nearest site. Each
#AHA25 Excited to present our work from @MCG_AUG with my team: “Unequal Access: Socioeconomic Deprivation & Travel Distance to Phase III Lipid-Lowering Trials in the Southern U.S.” Join me for my moderated poster session on Mon, Nov 10 (2:06–2:11 PM CT, Population Science Zone)!
1
6
10
Excited for this discussion. Being presented now at #AHA25 by @adibhave1357 and simpub at @JAMANetworkOpen - see links below for more details - post pre AHA- https://t.co/exwkU42JFr - post of the presenter- https://t.co/Z8hELsn0BH - simpub:
jamanetwork.com
This systematic review and meta-analysis compares the incidence of cardiotoxic effects of antibody-drug conjugates vs standard chemotherapy regimens for erb-b2 receptor tyrosine kinase 2 (ERBB2)���po...
How do you manage antiHer2 therapy in pts with low EF 30-40% (that are medically optimized from cardiac perspective)? Clinical N2 Her2+, HR- breast cancer, ECOG 0-1 @stolaney1 @PTarantinoMD @ErikaHamilton9 @sdent_cardioonc @avirupguha @dr_yakupergun @BijoyTelivala #bcsm
0
4
11
Presentation #5 on last day of #AHA25 by @dukemedicine #SarahMalik from @MCG_AUG - Take home - In 12,832 #ARIC participants followed for 28 years, 877 cancer survivors and 3,653 non-cancer participants developed incident CVD. Across both unmatched and propensity-matched analyses,
#AHA25 #CardioOncology Excited to highlight our lab’s #ARIC-cancer work by Dr. Sarah Malik and team: “The Use of Common Cardiovascular Medications Is Associated with a Comparable Decrease in CVD Risk in Cancer Survivors and Non-Cancer Patients.” Join her moderated presentation on
1
4
16
In this meta-analysis, trastuzumab emtansine had the lowest incidence of cardiotoxic LV dysfunction (1.09%) compared to trastuzumab deruxtecan (4.20%) and standard trastuzumab-containing regimens. Full publication available here: https://t.co/osWHE6zZCh
@JAMANetworkOpen #AHA25
0
3
4
Third moderated poster by @OelsayedMD presenting moderated digital poster - take home #1 Among 14,834 ARIC participants followed for 25 years, 54% were classified as obese by the newer central adiposity definition versus 27% by the traditional BMI-based definition. The newly
Obesity is an important overlap between cancer and cardiovascular disease. We talk about it here: https://t.co/1UXtFpAGas. How does the new WHO definition: https://t.co/M4SKpLcDxm of obesity shake up this risk factor- come and learn from @OelsayedMD at #AHA25 @AHAScience
1
5
13
Presentation #4 for today: by another super star postdoc @TarekNahle - take home : Among 283K breast cancer pts (SEER 2010–15), CV mortality declined across stages I–III. 💊 Chemo (±RT) linked to lower CVM vs RT alone in: •Luminal A (Stage II–III) •Luminal B (Stage II) •TNBC
Excited to share an @AUG_University/@WellstarHealth study at #AHA25. Join us for the presentation, “Treatment Modality and Cardiovascular Mortality in Breast Cancer: A SEER & Single-Center Analysis by Stage & Receptor Subtype” on November 9th 🔗 https://t.co/qFf25VatWf
0
5
13
Second presentation for the day by superstar @virajshahr - take home - Among 3,192 African American ARIC participants followed for 22.4 years, 30% developed cancer. The DARC-positive genotype was not significantly associated with overall, smoking-related, or obesity-related
Come, check out our work funded by @AHAScience #SFRN. Learn about role of ancestral gene ACKR1 and how that changes cancer risk in those with cardiovascular disease. Previously we had shown the role of neutrophil to lymphocyte ratio. We were fortunate to collaborate with.@MeliD32
0
7
15
On the eve of #AHA25, I am happy to report a new paper from our lab looking to replace CHADSVASC for AF in breast cancer. Published in @Cancers_MDPI - BS2CALED - In breast cancer + AF, B‑S2CALED predicts stroke/TIA better than CHA2DS2‑VASc and is externally validated. Simple 0–10
1
11
26
Why use this calculator? CHA2DS2‑VASc underperforms in cancer. B‑S2CALED improves discrimination (C‑index 0.64 vs 0.54 internal; 0.77 vs 0.53 external) + reclassification, with 3 tiers (0 none, 1–4 low/intermediate, >4 high). #CardioOncology #BreastCancer @ICOSociety @datsunian
0
3
6
Find us #AHA25 (CT): Sun 11/9 11:57–12:02 @adibhave1357 HER2 ADC cardiotoxicity ( Mod poster and @JAMANetworkOpen simpub) 3:15–3:20 @OelsayedMD obesity cancer/cvd (#11 Mod post) 3:15 @VirajShahr ACKR1/DARC (post) 3:50–3:55 @TarekNahle BrCa SEER (#10 Mod poster) @ICOSociety
1
7
20
Based on core concept funded by @CDMRP PCRP PRA - @DocHariKris did this outstanding work (one of its kind work) with Aaron Kruse-Diehr from @AUG_SPH #implementationscience #carddioonc
1/4 🚨 New in Current Treatment Options in Oncology! Our review “Social Determinants of Health in Cardio-Oncology: From Evidence to Action” tackles one key question: 👉 How do we move from recognising inequities to fixing them? https://t.co/vht2S8MKV3
@avirupguha
1
3
6
Our review on implementation science in Cardio-Oncology was the most read article in Current Treatment Options in Oncology this week! “Social Determinants of Health in Cardio-Oncology: From Evidence to Action” Read here: https://t.co/ZesgpIUV3R Please feel free to reach out or
1/4 🚨 New in Current Treatment Options in Oncology! Our review “Social Determinants of Health in Cardio-Oncology: From Evidence to Action” tackles one key question: 👉 How do we move from recognising inequities to fixing them? https://t.co/vht2S8MKV3
@avirupguha
0
6
10
1/4 🚨 New in Current Treatment Options in Oncology! Our review “Social Determinants of Health in Cardio-Oncology: From Evidence to Action” tackles one key question: 👉 How do we move from recognising inequities to fixing them? https://t.co/vht2S8MKV3
@avirupguha
1
1
2
2/4 Cardio-oncology has advanced rapidly, but equity hasn’t kept pace. Patients’ outcomes still depend on where they live, what they earn, and whether they can reach care. This is the implementation gap between evidence and practice. @virajshahr @TarekNahle
#HealthEquity
1
1
2
#AHA25 #CardioOncology Excited to highlight our lab’s #ARIC-cancer work by Dr. Sarah Malik and team: “The Use of Common Cardiovascular Medications Is Associated with a Comparable Decrease in CVD Risk in Cancer Survivors and Non-Cancer Patients.” Join her moderated presentation on
0
1
5
@TarekNahle @AUG_University @WellstarHealth @avirupguha @virajshahr @OelsayedMD @sdent_cardioonc @husam247 @neerajaiims We would like to inform you that your post has been published on https://t.co/igx4msE1Ge. Thank you for sharing. https://t.co/wRD9UCM0UT
oncodaily.com
Tarek Nahle: Augusta University Study on Cardiovascular Mortality in Breast Cancer at AHA 2025 / Breast Cancer, cancer, CardioOncology, OncoDaily, Oncology,
0
2
3